Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

📆 01.11.2023 13:31:00
📰 MarketWatch

⏱ Reading Time:
25 sec. here
2 min. at publisher
📊 Quality Score:
News: 13%
Publisher: 97%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

The U.S.-listed shares of Cellectis S.A.

rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZeneca PLC AZN, +0.46% as part of a collaboration agreement that leverages Cellectis’ gene editing technologies. Trading volume ballooned to 10.8 million shares, compared with the full-day average of about 68,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges ahead of the open.

Schreibe Kommentar

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

Revvity’s stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlookTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Herkunft: MarketWatch - 🏆 3. / 97 Weiterlesen »